Kura Oncology/KURA

$17.53

-0.84%
-
1D1W1MYTD1YMAX

About Kura Oncology

Kura Oncology, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on precision medicine for the treatment of cancer. Its pipeline consists of small molecule product candidates that target cancer signaling pathways. Its product candidates include Ziftomenib, Tipifarnib and KO-2806. Ziftomenib, is a potent, selective, reversible and oral small molecule inhibitor that blocks the interaction of two proteins, menin and the protein expressed by the Lysine K-specific Methyl Transferase 2A gene, or KMT2A gene. Ziftomenib is a once-daily, oral drug candidate targeting the menin-KMT2A protein-protein interaction for the treatment of genetically defined acute myeloid leukemia patients with high unmet need. Tipifarnib is a potent, selective and orally bioavailable farnesyl transferase inhibitor (FTI). The KO-2806 is a next-generation FTI, which demonstrates improved potency, pharmacokinetic and physicochemical properties relative to earlier FTI drug candidates.

Ticker

KURA

Sector

Healthcare

Trading on

NASDAQ

Industry

Biotechnology & Drugs

CEO

Troy Wilson

Employees

142

Headquarters

San diego, United States

Kura Oncology Metrics

BasicAdvanced
$1.37B
Market cap
-
P/E ratio
-$2.08
EPS
0.91
Beta
-
Dividend rate
$1.37B
0.91163
$24.17
$7.41
1.39M
12.264
2.349
2.349
-33.72%
-37.34%
-36.09%
3.367
3.45
-2.73%

What the Analysts think about Kura Oncology

Analyst Ratings

Majority rating from 14 analysts.
Buy

Price Targets

Average projection from 12 analysts.
72.56% upside
High $37.00
Low $21.00
$17.53
Current price
$30.25
Average price target

Kura Oncology Financial Performance

Income StatementBalance sheetCash Flow

Income Statement

Revenues and expenses
0% profit margin
QuarterlyAnnual
Q4 23
QoQ growth
Revenue
$0
-
Net income
$-42.7M
10.62%
Profit margin
0%
-

Kura Oncology Earnings Performance

Earnings per share (EPS)

Company profitability
Missed by 0.13%
QuarterlyAnnual
Q1 23
Q2 23
Q3 23
Q4 23
Q1 24
Actual
-$0.50
-$0.53
-$0.50
-$0.55
-
Expected
-$0.54
-$0.55
-$0.55
-$0.55
-$0.55
Surprise
-8.07%
-3.62%
-9%
0.13%
-
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real time US market data is a consolidated feed of IEX, NYSE National, NYSE Chicago, Nasdaq BX and Nasdaq PSX order books provided by Polygon. Fundamental data, financials and analyst ratings are sourced from Refinitiv.

Upcoming events

FAQs

What’s the current market cap for Kura Oncology stock?

Kura Oncology (KURA) has a market cap of $1.35B as of April 20, 2024.

What is the P/E ratio for Kura Oncology stock?

The price to earnings (P/E) ratio for Kura Oncology (KURA) stock is 0 as of April 20, 2024.

Does Kura Oncology stock pay dividends?

No, Kura Oncology (KURA) stock does not pay dividends to its shareholders as of April 20, 2024.

When is the next Kura Oncology dividend payment date?

Kura Oncology (KURA) stock does not pay dividends to its shareholders.

What is the beta indicator for Kura Oncology?

Kura Oncology (KURA) has a beta rating of 0.92. This means that it is less volatile than the market, on average. A beta of 1 would indicate the stock moves in-line with the market, while a beta of 0.5 would mean it moves half as much as the market.

What is the Kura Oncology stock price target?

The target price for Kura Oncology (KURA) stock is $30.25, which is 72.56% above the current price of $17.53. This is an average based on projections from 12 analysts, and represents their view of what the stock price could be in 12 or 18 months. This should not be seen as investment advice - Lightyear does not carry out investment research.

Buy or sell Kura Oncology stock

Buy or sell Kura Oncology stock

Stocks, funds and up to 4.50% interest earned on uninvested cash. When you invest, your capital is at risk.
Start investing